$RARE
Ultragenyx Pharmaceutical Inc. Stock $rare

$rare Overview Financials Valuation SEC Filings Company Website

2022 Q4 Form 10-Q Financial Statement

#000095017022021366 Filed on November 03, 2022

Income Statement

Concept	2022 Q4	2022 Q3	2021 Q3
Revenue	$103.3M	$90.70M	$81.65M
YoY Change	23.93%	11.09%	0.22%
Cost Of Revenue	$5.319M	$8.631M	$4.175M
YoY Change	51.58%	106.73%	77.66%
Gross Profit	$98.03M	$82.07M	$77.47M
YoY Change	22.72%	5.94%	-2.08%
Gross Profit Margin	94.85%	90.48%	94.89%
Selling, General & Admin	$72.85M	$69.84M	$53.88M
YoY Change	22.58%	29.62%	27.92%
% of Gross Profit	74.31%	85.1%	69.55%
Research & Development	$170.8M	$237.3M	$113.4M
YoY Change	38.85%	109.23%	29.9%
% of Gross Profit	174.24%	289.13%	146.4%
Depreciation & Amortization	$4.957M	$4.694M	$3.217M
YoY Change	40.27%	45.91%	4.11%
% of Gross Profit	5.06%	5.72%	4.15%
Operating Expenses	$243.7M	$307.1M	$167.3M
YoY Change	33.55%	83.59%	26.95%
Operating Profit	-$145.6M	-$225.1M	-$89.83M
YoY Change	41.99%	150.55%	78.53%
Interest Expense	$8.038M	$1.857M	$26.11M
YoY Change	-151.33%	-92.89%	-356.48%
% of Operating Profit
Other Income/Expense, Net	-$15.69M	-$1.105M	-$415.0K
YoY Change	272.43%	166.27%	-175.87%
Pretax Income	-$153.3M	-$238.8M	-$72.82M
YoY Change	25.19%	227.98%	6.25%
Income Tax	-$1.451M	$6.287M	$182.0K
% Of Pretax Income
Net Earnings	-$151.8M	-$245.1M	-$73.00M
YoY Change	23.99%	235.77%	6.03%
Net Earnings / Revenue	-146.91%	-270.23%	-89.41%
Basic Earnings Per Share		-$3.50	-$1.08
Diluted Earnings Per Share	-$2.16	-$3.50	-$1.075M
COMMON SHARES
Basic Shares Outstanding	70.11M	70.04M	67.88M
Diluted Shares Outstanding		70.05M	67.88M

Balance Sheet

Concept	2022 Q4	2022 Q3	2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$747.8M	$888.7M	$737.1M
YoY Change	1.02%	20.56%	-3.71%
Cash & Equivalents	$132.9M	$391.7M	$197.5M
Short-Term Investments	$614.8M	$497.0M	$539.6M
Other Short-Term Assets	$68.93M	$70.98M	$69.19M
YoY Change	-3.93%	2.58%	7.78%
Inventory	$26.77M	$21.85M	$15.19M
Prepaid Expenses
Receivables	$40.45M	$31.16M	$25.38M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$883.9M	$1.013B	$846.9M
YoY Change	3.19%	19.58%	-2.88%
LONG-TERM ASSETS
Property, Plant & Equipment	$259.7M	$234.6M	$119.1M
YoY Change	83.88%	97.04%	37.81%
Goodwill	$44.41M	$44.41M	$44.41M
YoY Change	0.0%	0.0%
Intangibles	$160.1M	$158.4M	$130.9M
YoY Change	22.42%	21.04%
Long-Term Investments	$154.5M	$121.3M	$290.5M
YoY Change	-47.42%	-58.22%	124.64%
Other Assets	$16.85M	$18.29M	$16.42M
YoY Change	-18.06%	11.36%	222.45%
Total Long-Term Assets	$661.5M	$605.8M	$637.9M
YoY Change	-0.64%	-5.03%	60.93%
TOTAL ASSETS
Total Short-Term Assets	$883.9M	$1.013B	$846.9M
Total Long-Term Assets	$661.5M	$605.8M	$637.9M
Total Assets	$1.545B	$1.618B	$1.485B
YoY Change	1.51%	9.0%	17.06%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$43.27M	$23.53M	$15.58M
YoY Change	152.5%	51.09%	43.55%
Accrued Expenses	$204.7M	$189.1M	$109.7M
YoY Change	40.62%	72.4%	37.67%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$261.2M	$227.4M	$135.9M
YoY Change	44.02%	67.26%	-32.44%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change	-100.0%
Other Long-Term Liabilities	$4.820M	$4.050M	$471.0K
YoY Change	379.6%	759.87%	-99.87%
Total Long-Term Liabilities	$4.820M	$4.050M	$471.0K
YoY Change	379.6%	759.87%	-99.87%
TOTAL LIABILITIES
Total Short-Term Liabilities	$261.2M	$227.4M	$135.9M
Total Long-Term Liabilities	$4.820M	$4.050M	$471.0K
Total Liabilities	$1.193B	$1.150B	$551.1M
YoY Change	98.88%	108.6%	-8.48%
SHAREHOLDERS EQUITY
Retained Earnings	-$2.781B	-$2.629B	-$1.951B
YoY Change	34.12%	34.75%
Common Stock	$70.00K	$70.00K	$68.00K
YoY Change	1.45%	2.94%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$0.00
YoY Change
Treasury Stock Shares	$0.00
Shareholders Equity	$352.5M	$468.8M	$933.7M
YoY Change
Total Liabilities & Shareholders Equity	$1.545B	$1.618B	$1.485B
YoY Change	1.51%	9.0%	17.06%

Cashflow Statement

Concept	2022 Q4	2022 Q3	2021 Q3
OPERATING ACTIVITIES
Net Income	-$151.8M	-$245.1M	-$73.00M
YoY Change	23.99%	235.77%	6.03%
Depreciation, Depletion And Amortization	$4.957M	$4.694M	$3.217M
YoY Change	40.27%	45.91%	4.11%
Cash From Operating Activities	-$90.34M	-$95.35M	-$59.65M
YoY Change	66.24%	59.84%	-3.75%
INVESTING ACTIVITIES
Capital Expenditures	$26.97M	-$26.05M	-$20.56M
YoY Change	-268.06%	26.68%	239.83%
Acquisitions
YoY Change
Other Investing Activities	-$144.6M	-$135.8M	-$20.20M
YoY Change	-269.94%	572.37%	-77.48%
Cash From Investing Activities	-$171.6M	-$161.9M	-$40.76M
YoY Change	-348.49%	297.11%	-57.44%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	1.882M	491.9M	7.550M
YoY Change	-97.8%	6414.93%	-60.53%
NET CHANGE
Cash From Operating Activities	-90.34M	-95.35M	-59.65M
Cash From Investing Activities	-171.6M	-161.9M	-40.76M
Cash From Financing Activities	1.882M	491.9M	7.550M
Net Change In Cash	-260.1M	234.7M	-92.86M
YoY Change	-358.92%	-352.72%	-33.0%
FREE CASH FLOW
Cash From Operating Activities	-$90.34M	-$95.35M	-$59.65M
Capital Expenditures	$26.97M	-$26.05M	-$20.56M
Free Cash Flow	-$117.3M	-$69.30M	-$39.09M
YoY Change	206.33%	77.29%	-30.1%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
CY2022Q3	us-gaap	Restricted Cash And Cash Equivalents Current Asset Statement Of Financial Position Extensible List RestrictedCashAndCashEquivalentsCurrentAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#PrepaidExpenseAndOtherAssetsCurrent
CY2021Q3	us-gaap	Restricted Cash And Cash Equivalents Noncurrent Asset Statement Of Financial Position Extensible List RestrictedCashAndCashEquivalentsNoncurrentAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent
CY2021Q3	us-gaap	Restricted Cash And Cash Equivalents Current Asset Statement Of Financial Position Extensible List RestrictedCashAndCashEquivalentsCurrentAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#PrepaidExpenseAndOtherAssetsCurrent
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Amendment Flag AmendmentFlag	false
	dei	Entity Central Index Key EntityCentralIndexKey	0001515673
CY2022Q3	us-gaap	Restricted Cash And Cash Equivalents Noncurrent Asset Statement Of Financial Position Extensible List RestrictedCashAndCashEquivalentsNoncurrentAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-36276
	dei	Entity Registrant Name EntityRegistrantName	ULTRAGENYX PHARMACEUTICAL INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	27-2546083
	dei	Entity Address Address Line1 EntityAddressAddressLine1	60 Leveroni Court
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94949
	dei	City Area Code CityAreaCode	415
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	8812000
	us-gaap	Net Income Loss NetIncomeLoss	-555588000
	us-gaap	Net Income Loss NetIncomeLoss	-331567000
	dei	Entity Address City Or Town EntityAddressCityOrTown	Novato
CY2021Q4	rare	Equity Investments Noncurrent EquityInvestmentsNoncurrent	34925000
CY2022Q3	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	107563000
	dei	Local Phone Number LocalPhoneNumber	483-8800
	dei	Security12b Title Security12bTitle	Common Stock, $0.001 par value
	dei	Trading Symbol TradingSymbol	RARE
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	false
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	70105654
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	391651000
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	307584000
CY2022Q3	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	497024000
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	432612000
CY2022Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	31164000
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	28432000
CY2022Q3	us-gaap	Inventory Net InventoryNet	21849000
CY2021Q4	us-gaap	Inventory Net InventoryNet	16231000
CY2022Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	70980000
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	71745000
CY2022Q3	us-gaap	Assets Current AssetsCurrent	1012668000
CY2021Q4	us-gaap	Assets Current AssetsCurrent	856604000
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	234614000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	141247000
CY2022Q3	rare	Equity Investments Noncurrent EquityInvestmentsNoncurrent	13786000
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	258933000
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	28751000
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	34936000
CY2022Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	158401000
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	130788000
CY2022Q3	us-gaap	Goodwill Goodwill	44406000
CY2021Q4	us-gaap	Goodwill Goodwill	44406000
CY2022Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	18285000
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	20558000
CY2022Q3	us-gaap	Assets Assets	1618474000
CY2021Q4	us-gaap	Assets Assets	1522397000
CY2022Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	23533000
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	17138000
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	189051000
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	145555000
CY2022Q3	rare	Contract Liabilities Current ContractLiabilitiesCurrent	2958000
CY2021Q4	rare	Contract Liabilities Current ContractLiabilitiesCurrent	7609000
CY2022Q3	rare	Operating And Finance Lease Liability Current OperatingAndFinanceLeaseLiabilityCurrent	11819000
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	69000
CY2021Q4	rare	Operating And Finance Lease Liability Current OperatingAndFinanceLeaseLiabilityCurrent	11066000
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	227361000
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	181368000
CY2022Q3	rare	Contract Liabilities Noncurrent ContractLiabilitiesNoncurrent	0
CY2021Q4	rare	Contract Liabilities Noncurrent ContractLiabilitiesNoncurrent	1467000
CY2022Q3	rare	Operating And Finance Lease Liability Noncurrent OperatingAndFinanceLeaseLiabilityNoncurrent	22865000
CY2021Q4	rare	Operating And Finance Lease Liability Noncurrent OperatingAndFinanceLeaseLiabilityNoncurrent	30904000
CY2022Q3	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	33306000
CY2021Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	33306000
CY2022Q3	rare	Liability Related To Sale Of Future Royalties LiabilityRelatedToSaleOfFutureRoyalties	862063000
CY2021Q4	rare	Liability Related To Sale Of Future Royalties LiabilityRelatedToSaleOfFutureRoyalties	351786000
CY2022Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	4050000
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1005000
CY2022Q3	us-gaap	Liabilities Liabilities	1149645000
CY2021Q4	us-gaap	Liabilities Liabilities	599836000
CY2022Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000
CY2022Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2022Q3	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	70079777
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	70079777
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	69344998
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	69344998
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	70000
CY2022Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	3108170000
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	2997497000
CY2022Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-10222000
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1404000
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-2629189000
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-2073601000
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	468829000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	922561000
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1618474000
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1522397000
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	90703000
CY2021Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	81647000
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	259981000
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	268017000
CY2022Q3	rare	Cost Of Sales CostOfSales	8631000
CY2021Q3	rare	Cost Of Sales CostOfSales	4175000
	rare	Cost Of Sales CostOfSales	23001000
	rare	Cost Of Sales CostOfSales	12499000
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	237297000
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.08
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-7.96
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-7.96
CY2021Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	113417000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	534981000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	374140000
CY2022Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	69841000
CY2021Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	53883000
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	205290000
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	160551000
CY2022Q3	rare	Cost Of Sales And Operating Expenses CostOfSalesAndOperatingExpenses	315769000
CY2021Q3	rare	Cost Of Sales And Operating Expenses CostOfSalesAndOperatingExpenses	171475000
	rare	Cost Of Sales And Operating Expenses CostOfSalesAndOperatingExpenses	763272000
	rare	Cost Of Sales And Operating Expenses CostOfSalesAndOperatingExpenses	547190000
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-225066000
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-89828000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-503291000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-279173000
CY2022Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	3483000
CY2021Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	408000
	us-gaap	Investment Income Interest InvestmentIncomeInterest	4876000
	us-gaap	Investment Income Interest InvestmentIncomeInterest	1488000
CY2022Q3	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	-1626000
CY2021Q3	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	25702000
	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	-21139000
	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	-25963000
CY2022Q3	rare	Non Cash Interest Expense On Liability Related To Sale Of Future Royalties NonCashInterestExpenseOnLiabilityRelatedToSaleOfFutureRoyalties	14505000
CY2021Q3	rare	Non Cash Interest Expense On Liability Related To Sale Of Future Royalties NonCashInterestExpenseOnLiabilityRelatedToSaleOfFutureRoyalties	8683000
	rare	Non Cash Interest Expense On Liability Related To Sale Of Future Royalties NonCashInterestExpenseOnLiabilityRelatedToSaleOfFutureRoyalties	27141000
	rare	Non Cash Interest Expense On Liability Related To Sale Of Future Royalties NonCashInterestExpenseOnLiabilityRelatedToSaleOfFutureRoyalties	25618000
CY2022Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1105000
CY2021Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-415000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1746000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1277000
CY2022Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-238819000
CY2021Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-72816000
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-548441000
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-330543000
CY2022Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	6287000
CY2021Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	182000
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	7147000
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1024000
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-245106000
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-72998000
	us-gaap	Net Income Loss NetIncomeLoss	-555588000
	us-gaap	Net Income Loss NetIncomeLoss	-331567000
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.50
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.50
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.08
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-4.91
CY2022Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-246414000
CY2021Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-73176000
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-4.91
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	70054173
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-564406000
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	70054173
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-332202000
	rare	Issuance Of Common Stock Under Equity Plan Awards Net Of Tax IssuanceOfCommonStockUnderEquityPlanAwardsNetOfTax	33177000
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-635000
	us-gaap	Net Income Loss NetIncomeLoss	-331567000
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	67875363
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	67875363
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	69834037
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	69834037
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	67533671
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	67533671
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-245106000
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-72998000
	us-gaap	Net Income Loss NetIncomeLoss	-555588000
	us-gaap	Net Income Loss NetIncomeLoss	-331567000
CY2022Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-420000
CY2021Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-166000
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-1211000
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-348000
CY2022Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-888000
CY2021Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-12000
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-7607000
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-287000
CY2022Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-1308000
CY2021Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-178000
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-8818000
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-635000
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	678073000
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	36096000
CY2022Q3	rare	Issuance Of Common Stock Under Equity Plan Awards Net Of Tax IssuanceOfCommonStockUnderEquityPlanAwardsNetOfTax	1074000
CY2022Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-1308000
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-245106000
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	468829000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	922561000
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	101862000
	rare	Issuance Of Common Stock Under Equity Plan Awards Net Of Tax IssuanceOfCommonStockUnderEquityPlanAwardsNetOfTax	8812000
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-8818000
	us-gaap	Net Income Loss NetIncomeLoss	-555588000
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	468829000
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	972171000
CY2021Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	27005000
CY2021Q3	rare	Issuance Of Common Stock Under Equity Plan Awards Net Of Tax IssuanceOfCommonStockUnderEquityPlanAwardsNetOfTax	7674000
CY2021Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-178000
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-72998000
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	933674000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	1154375000
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	78324000
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	933674000
	rare	Increase Decrease In Accounts Payable Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccountsPayableAccruedLiabilitiesAndOtherOperatingLiabilities	52416000
	rare	Increase Decrease In Accounts Payable Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccountsPayableAccruedLiabilitiesAndOtherOperatingLiabilities	1920000
	rare	Increase Decrease In Contract Liabilities IncreaseDecreaseInContractLiabilities	-6118000
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	33177000
	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-436000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-558000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	6979000
	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-350000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	499326000
	rare	Allocated Share Based Compensation Expense Net Of Capitalized Inventory Cost AllocatedShareBasedCompensationExpenseNetOfCapitalizedInventoryCost	101022000
	rare	Allocated Share Based Compensation Expense Net Of Capitalized Inventory Cost AllocatedShareBasedCompensationExpenseNetOfCapitalizedInventoryCost	78133000
	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	75234000
	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	0
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-4349000
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-4499000
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	13263000
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	9705000
	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	-21139000
	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	-25963000
	rare	Non Cash Collaboration Royalty Revenue NonCashCollaborationRoyaltyRevenue	15634000
	rare	Non Cash Collaboration Royalty Revenue NonCashCollaborationRoyaltyRevenue	13210000
	rare	Non Cash Interest Expense On Liability Related To Sale Of Future Royalties NonCashInterestExpenseOnLiabilityRelatedToSaleOfFutureRoyalties	27141000
	rare	Non Cash Interest Expense On Liability Related To Sale Of Future Royalties NonCashInterestExpenseOnLiabilityRelatedToSaleOfFutureRoyalties	25618000
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-564000
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-433000
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	2973000
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	2362000
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	5496000
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2127000
	rare	Increase Decrease In Contract Liabilities IncreaseDecreaseInContractLiabilities	-74377000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-290123000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-284351000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	89153000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	57045000
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	75391000
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	416161000
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	917409000
	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	82966000
	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	83318000
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	407926000
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	583997000
	rare	Proceeds From Sale Of Equity Investment ProceedsFromSaleOfEquityInvestment	0
	rare	Proceeds From Sale Of Equity Investment ProceedsFromSaleOfEquityInvestment	43197000
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	30000000
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0
	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	240000
	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	487000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-120053000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-264429000
	rare	Proceeds From Royalties Received Financing Activities ProceedsFromRoyaltiesReceivedFinancingActivities	490950000
	rare	Proceeds From Royalties Received Financing Activities ProceedsFromRoyaltiesReceivedFinancingActivities	0
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	32827000
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	391651000
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-2427000
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-802000
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	86723000
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-516755000
CY2021Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	197538000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	309585000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	726294000
CY2022Q3	us-gaap	Restricted Cash Current RestrictedCashCurrent	517000
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	396308000
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	209539000
	rare	Operating And Finance Lease Liability From Obtaining Right Of Use Assets OperatingAndFinanceLeaseLiabilityFromObtainingRightOfUseAssets	1168000
	rare	Operating And Finance Lease Liability From Obtaining Right Of Use Assets OperatingAndFinanceLeaseLiabilityFromObtainingRightOfUseAssets	2610000
	rare	Non Cash Interest Expense On Liability Related To The Sale Of Future Royalties Capitalized Into Ending Property Plant And Equipment NonCashInterestExpenseOnLiabilityRelatedToTheSaleOfFutureRoyaltiesCapitalizedIntoEndingPropertyPlantAndEquipment	7820000
	rare	Non Cash Interest Expense On Liability Related To The Sale Of Future Royalties Capitalized Into Ending Property Plant And Equipment NonCashInterestExpenseOnLiabilityRelatedToTheSaleOfFutureRoyaltiesCapitalizedIntoEndingPropertyPlantAndEquipment	0
	us-gaap	Nature Of Operations NatureOfOperations	<p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Calibri", sans-serif;min-width:fit-content;">1. Organization</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Calibri", sans-serif;min-width:fit-content;">Ultragenyx Pharmaceutical Inc. (the Company) is a biopharmaceutical company incorporated in Delaware.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Calibri", sans-serif;min-width:fit-content;">The Company is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. The Company operates as </span><span style="font-size:10.0pt;font-family:"Calibri", sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Calibri", sans-serif;min-width:fit-content;">one</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Calibri", sans-serif;min-width:fit-content;"> reportable segment. The Company has four commercially approved products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Calibri", sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Calibri", sans-serif;min-width:fit-content;">Crysvita® (burosumab) is approved in the United States (U.S.) by the U.S. Food and Drug Administration (FDA) and Canada for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients one year of age and older, and is approved in the European Union (EU) and the United Kingdom (U.K.), for the treatment of XLH with radiographic evidence of bone disease in children one year of age and older, adolescents, and adults. In Brazil, Colombia, Mexico, Chile, Peru, and Argentina, Crysvita is approved for treatment of XLH in adult and pediatric patients one year of age and older. Crysvita is also approved in the U.S. by the FDA and in Canada and Peru for the treatment of fibroblast growth factor 23 (FGF23)-related hypophosphatemia in tumor-induced osteomalacia (TIO), associated with phosphaturic mesenchymal tumors that cannot be curatively resected or localized in adults and pediatric patients 2 years of age and older.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Calibri", sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Calibri", sans-serif;min-width:fit-content;">Mepsevii® (vestronidase alfa) is approved by the FDA as the first medicine for the treatment of children and adults with mucopolysaccharidosis VII (MPS VII), also known as Sly syndrome. In the EU and the U.K., Mepsevii is approved under exceptional circumstances for patients of all ages for the treatment of non-neurological manifestations of MPS VII. In Brazil, Mexico, and Japan Mepsevii is approved for the treatment of MPS VII for patients of all ages.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Calibri", sans-serif;min-width:fit-content;">Dojolvi® (triheptanoin) is approved in the U.S., Canada, and Brazil for the treatment of pediatric and adult patients severely affected by long-chain fatty acid oxidation disorders (LC-FAOD).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Calibri", sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Calibri", sans-serif;min-width:fit-content;">Evkeeza® (evinacumab) is approved in the U.S. and the European Economic Area (EEA) for the treatment of homozygous familial hypercholesterolemia (HoFH). In January 2022, the Company licensed exclusive rights from Regeneron Pharmaceuticals (Regeneron) to commercialize Evkeeza® (evinacumab) outside of the U.S.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Calibri", sans-serif;min-width:fit-content;">The Company also has the following ongoing clinical development programs:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Calibri", sans-serif;min-width:fit-content;"> </span></p><div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:4.5pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Calibri", sans-serif;min-width:fit-content;">UX111 (formerly ABO-102) is an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A (MPS IIIA), a rare lysosomal storage disease. In May 2022, the Company announced an exclusive license agreement with Abeona Therapeutics Inc. (Abeona) for UX111 whereby the Company assumed responsibility for the UX111 program, as further described in Note 7;</span></div></div><div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:4.5pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Calibri", sans-serif;min-width:fit-content;">DTX401 is an adeno-associated virus 8 (AAV8) gene therapy product candidate for the treatment of patients with glycogen storage disease type Ia (GSDIa);</span></div></div><div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:4.5pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Calibri", sans-serif;min-width:fit-content;">DTX301 is an AAV8 gene therapy product candidate in development for the treatment of patients with ornithine transcarbamylase (OTC) deficiency, the most common urea cycle disorder;</span></div></div><div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:4.5pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Calibri", sans-serif;min-width:fit-content;">UX143 (setrusumab), which is subject to the Company</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:"Calibri", sans-serif;min-width:fit-content;">’</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Calibri", sans-serif;min-width:fit-content;">s collaboration agreement with Mereo BioPharma 3 (Mereo), is a fully human monoclonal antibody that inhibits sclerostin, a protein that acts on a key bone-signaling pathway and inhibits the activity of bone-forming cells for the treatment of patients with osteogenesis imperfect (OI); </span></div></div><div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:4.5pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Calibri", sans-serif;min-width:fit-content;">GTX-102 is an antisense oligonucleotide (ASO), which the Company is developing through GeneTx Biotherapeutics LLC (GeneTx) for the treatment of Angelman syndrome, a debilitating and rare neurogenetic disorder caused by loss-of-function of the maternally inherited allele of the UBE3A gene. In July 2022, the Company executed its option to acquire GeneTx as further described in Note 6;</span></div></div><div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:4.5pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Calibri", sans-serif;min-width:fit-content;">UX701 is an adeno-associated virus 9, (AAV9) gene therapy designed to deliver stable expression of a truncated version of the ATP7B copper transporter following a single intravenous infusion to improve copper distribution and excretion from the body and reverse pathological findings of Wilson liver disease; and</span></div></div><div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:4.5pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Calibri", sans-serif;min-width:fit-content;">UX053 is a messenger RNA (mRNA) product candidate designed for the treatment of patients with Glycogen Storage Disease Type III (GSDIII), a disease caused by a glycogen debranching enzyme (AGL) deficiency that results in glycogen accumulation in the liver and muscle. </span></div></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Calibri", sans-serif;min-width:fit-content;">The Company has sustained operating losses and expects such annual losses to continue over the next several years. The Company</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:"Calibri", sans-serif;min-width:fit-content;">’</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Calibri", sans-serif;min-width:fit-content;">s ultimate success depends on the outcome of its research and development and commercialization activities. Management recognizes that the Company will likely need to raise additional capital to fully implement its business plans. Through September 30, 2022, the Company has relied primarily on its sale of equity securities, its revenues from commercial products, its sale of future royalties, and strategic collaboration arrangements to finance its operations.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Calibri", sans-serif;min-width:fit-content;">The Company expects it will need to raise additional capital through the issuance of equity, borrowings, or strategic alliances with partner companies. However, if such financing is not available at adequate levels, the Company would need to reevaluate its operating plans.</span></p>
	us-gaap	Use Of Estimates UseOfEstimates	<p style="text-indent:0.0%;font-size:10.0pt;margin-top:13.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Calibri", sans-serif;min-width:fit-content;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Calibri", sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Calibri", sans-serif;min-width:fit-content;">The accompanying Condensed Consolidated Financial Statements have been prepared in accordance with GAAP. The preparation of the Condensed Consolidated Financial Statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent liabilities and the reported amounts of expenses in the Condensed Consolidated Financial Statements and the accompanying notes. On an ongoing basis, management evaluates its estimates, including those related to clinical trial accruals, fair value of assets and liabilities, income taxes, stock-based compensation, revenue recognition, and liabilities related to the sale of future royalties. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could differ from those estimates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Calibri", sans-serif;min-width:fit-content;"> </span></p>
CY2021Q3	us-gaap	Restricted Cash Current RestrictedCashCurrent	10000000
CY2022Q3	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	4140000
CY2021Q3	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	2001000
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	396308000
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	209539000
CY2022Q3	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	990189000
CY2021Q4	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	1001451000
CY2021Q3	rare	Contract With Customer Assets Liability Current ContractWithCustomerAssetsLiabilityCurrent	7809000
CY2022Q3	rare	Percentage Of Gross Accounts Receivable Balance PercentageOfGrossAccountsReceivableBalance	0.49
CY2022Q3	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	983955000
CY2022Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	8000
CY2022Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	8898000
CY2022Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	975065000
CY2021Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	969592000
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	5000
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	1288000
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	968309000
CY2022Q3	us-gaap	Inventory Work In Process InventoryWorkInProcess	15777000
CY2021Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	10504000
CY2022Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	6072000
CY2021Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	5727000
CY2022Q3	us-gaap	Inventory Net InventoryNet	21849000
CY2021Q4	us-gaap	Inventory Net InventoryNet	16231000
CY2021Q4	rare	Percentage Of Gross Accounts Receivable Balance PercentageOfGrossAccountsReceivableBalance	0.71
CY2022Q3	rare	Research Clinical Study And Manufacturing Expenses ResearchClinicalStudyAndManufacturingExpenses	61921000
CY2021Q4	rare	Research Clinical Study And Manufacturing Expenses ResearchClinicalStudyAndManufacturingExpenses	40880000
CY2022Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	67197000
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	62591000
CY2022Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	59933000
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	42084000
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	189051000
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	145555000
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	90703000
CY2021Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	81647000
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	259981000
	rare	Percentage Of Gross Accounts Receivables From Different Customer PercentageOfGrossAccountsReceivablesFromDifferentCustomer	0.16
CY2021	rare	Percentage Of Gross Accounts Receivables From Different Customer PercentageOfGrossAccountsReceivablesFromDifferentCustomer	0
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	268017000
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	90703000
CY2021Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	81647000
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	259981000
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	268017000
CY2021Q4	rare	Contract With Customer Assets Liability Current ContractWithCustomerAssetsLiabilityCurrent	-9076000
CY2020Q4	rare	Contract With Customer Assets Liability Current ContractWithCustomerAssetsLiabilityCurrent	-66568000
	rare	Contract With Customer Assets Liability Additions During Period ContractWithCustomerAssetsLiabilityAdditionsDuringPeriod	-89000
	rare	Contract With Customer Assets Liability Additions During Period ContractWithCustomerAssetsLiabilityAdditionsDuringPeriod	-2390000
	rare	Contract With Customer Assets Liability Deductions During Period ContractWithCustomerAssetsLiabilityDeductionsDuringPeriod	6207000
	rare	Contract With Customer Assets Liability Deductions During Period ContractWithCustomerAssetsLiabilityDeductionsDuringPeriod	76767000
CY2022Q3	rare	Contract With Customer Assets Liability Current ContractWithCustomerAssetsLiabilityCurrent	-2958000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	78430000
CY2020Q4	rare	Liability Related To Sale Of Future Royalties LiabilityRelatedToSaleOfFutureRoyalties	335665000
CY2021	rare	Non Cash Collaboration Royalty Revenue NonCashCollaborationRoyaltyRevenue	17951000
CY2021	rare	Non Cash Interest Expense On Liability Related To Sale Of Future Royalties And Capitalized To Property Plant And Equipment NonCashInterestExpenseOnLiabilityRelatedToSaleOfFutureRoyaltiesAndCapitalizedToPropertyPlantAndEquipment	34072000
CY2021Q4	rare	Liability Related To Sale Of Future Royalties LiabilityRelatedToSaleOfFutureRoyalties	351786000
	rare	Proceeds From Royalties Received Financing Activities ProceedsFromRoyaltiesReceivedFinancingActivities	490950000
	rare	Non Cash Collaboration Royalty Revenue NonCashCollaborationRoyaltyRevenue	15634000
	rare	Non Cash Interest Expense On Liability Related To Sale Of Future Royalties And Capitalized To Property Plant And Equipment NonCashInterestExpenseOnLiabilityRelatedToSaleOfFutureRoyaltiesAndCapitalizedToPropertyPlantAndEquipment	34961000
CY2022Q3	rare	Liability Related To Sale Of Future Royalties LiabilityRelatedToSaleOfFutureRoyalties	862063000
CY2022Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	35761000
CY2021Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	26990000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	101013000
CY2022Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	12014181
CY2021Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8317206
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11129869
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8304317
	rare	Stock Issued During Period Shares At Market Offering StockIssuedDuringPeriodSharesAtMarketOffering	1050372
	rare	Proceeds From Issuance Of Common Stock At Market Offering ProceedsFromIssuanceOfCommonStockAtMarketOffering	78900000
CY2022Q3	rare	Related Party Payment Of Contribution RelatedPartyPaymentOfContribution	1000000.0
CY2022Q3	rare	Related Party Transaction Contribution Period RelatedPartyTransactionContributionPeriod	P4Y
CY2022Q3	us-gaap	Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax	-1332000
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax	-121000
CY2022Q3	us-gaap	Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-8890000
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-1283000
CY2022Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-10222000
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1404000

Files In Submission

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
0000950170-22-021366-index-headers.html	Edgar Link	pending
0000950170-22-021366-index.html	Edgar Link	pending
0000950170-22-021366.txt	Edgar Link	pending
0000950170-22-021366-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
img129315396_0.jpg	Edgar Link	pending
img130238917_0.jpg	Edgar Link	pending
img131162438_0.jpg	Edgar Link	pending
img132085959_0.jpg	Edgar Link	pending
img133009480_0.jpg	Edgar Link	pending
img133933001_0.jpg	Edgar Link	pending
img134856522_0.jpg	Edgar Link	pending
img215007471_0.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
rare-20220930.htm	Edgar Link	pending
rare-20220930.xsd	Edgar Link	pending
rare-ex10_1.htm	Edgar Link	pending
rare-ex10_2.htm	Edgar Link	pending
rare-ex10_3.htm	Edgar Link	pending
rare-ex10_4.htm	Edgar Link	pending
rare-ex10_5.htm	Edgar Link	pending
rare-ex10_6.htm	Edgar Link	pending
rare-ex10_7.htm	Edgar Link	pending
rare-ex10_8.htm	Edgar Link	pending
rare-ex10_9.htm	Edgar Link	pending
rare-ex31_1.htm	Edgar Link	pending
rare-ex31_2.htm	Edgar Link	pending
rare-ex32_1.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
rare-20220930_cal.xml	Edgar Link	unprocessable
rare-20220930_pre.xml	Edgar Link	unprocessable
rare-20220930_lab.xml	Edgar Link	unprocessable
rare-20220930_htm.xml	Edgar Link	completed
rare-20220930_def.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$RARE
Ultragenyx Pharmaceutical Inc. Stock $rare

2022 Q4 Form 10-Q Financial Statement

#000095017022021366 Filed on November 03, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RARE Ultragenyx Pharmaceutical Inc. Stock $rare

2022 Q4 Form 10-Q Financial Statement

#000095017022021366 Filed on November 03, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RARE
Ultragenyx Pharmaceutical Inc. Stock $rare